| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis (NCT07749768) | Ono Pharmaceutical Co., Ltd. | 2026-09-30 |
| A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. (NCT07734116) | Ono Pharmaceutical Co., Ltd. | 2026-08-15 |
| Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments (NCT07618377) | Ono Pharmaceutical Co., Ltd. | 2026-07-07 |
| IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) (NCT07104032) | Ono Pharmaceutical Co., Ltd. | 2026-06-12 |
| A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus (NCT07619157) | Ono Pharmaceutical Co., Ltd. | 2026-06-02 |
| A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds (NCT07594158) | Ono Pharmaceutical Co., Ltd. | 2026-05-30 |
| INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) (NCT07429266) | Ono Pharmaceutical Co., Ltd. | 2026-05-25 |
| A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) (NCT07169708) | Ono Pharmaceutical Co., Ltd. | 2026-03-20 |
| ONO-4538 Study in Patients With Richter's Transformation (NCT06936943) | Ono Pharmaceutical Co., Ltd. | 2025-11-19 |
| A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants (NCT07198087) | Ono Pharmaceutical Co., Ltd. | 2025-10-01 |
| A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia (NCT06803823) | Ono Pharmaceutical Co., Ltd. | 2025-05-01 |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease (NCT06881836) | Ono Pharmaceutical Co., Ltd. | 2025-04-24 |
| A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors (NCT06816108) | Ono Pharmaceutical Co., Ltd. | 2025-04-21 |
| A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis (NCT06752603) | Ono Pharmaceutical Co., Ltd. | 2025-04-02 |
| A Clinical Study of ONO-1110 in Patients With Fibromyalgia (NCT06752590) | Ono Pharmaceutical Co., Ltd. | 2025-03-26 |
| Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study (NCT06714370) | Ono Pharmaceutical Co., Ltd. | 2025-02-03 |
| A Study of ONO-1110 in Patients With Social Anxiety Disorder (NCT06805565) | Ono Pharmaceutical Co., Ltd. | 2025-01-31 |
| A Study of ONO-1110 in Patients With Major Depressive Disorder (NCT06792136) | Ono Pharmaceutical Co., Ltd. | 2025-01-16 |
| A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT06622226) | Ono Pharmaceutical Co., Ltd. | 2024-11-27 |
| Study to ONO-4538 in Patients With Rhabdoid Tumor (NCT06622941) | Ono Pharmaceutical Co., Ltd. | 2024-11-25 |
| Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL (NCT06541665) | Ono Pharmaceutical Co., Ltd. | 2024-05-17 |
| A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (NCT06256328) | Ono Pharmaceutical Co., Ltd. | 2024-01-10 |
| A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer (NCT06532331) | Ono Pharmaceutical Co., Ltd. | 2023-12-06 |
| A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL (NCT06547528) | Ono Pharmaceutical Co., Ltd. | 2023-10-01 |
| A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy (NCT05923866) | Ono Pharmaceutical Co., Ltd. | 2023-09-22 |
| A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL (NCT05515406) | Ono Pharmaceutical Co., Ltd. | 2023-02-13 |
| Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures (NCT06590896) | Ono Pharmaceutical Co., Ltd. | 2022-11-04 |
| ONO-4059 Study in Patients With Steroid-resistant Pemphigus (NCT06696716) | Ono Pharmaceutical Co., Ltd. | 2022-08-15 |
| ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. (NCT06579573) | Ono Pharmaceutical Co., Ltd. | 2022-07-12 |
| Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 (NCT05332704) | Ono Pharmaceutical Co., Ltd. | 2022-03-25 |
| Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors (NCT06535009) | Ono Pharmaceutical Co., Ltd. | 2022-02-08 |
| Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) (NCT04947319) | Ono Pharmaceutical Co., Ltd. | 2021-12-29 |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma (NCT05079282) | Ono Pharmaceutical Co., Ltd. | 2021-12-10 |
| ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (NCT06570031) | Ono Pharmaceutical Co., Ltd. | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (NCT05144854) | Ono Pharmaceutical Co., Ltd. | 2021-11-05 |
| The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer (NCT06540261) | Ono Pharmaceutical Co., Ltd. | 2021-09-23 |
| Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer (NCT06525246) | Ono Pharmaceutical Co., Ltd. | 2021-08-06 |
| An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (NCT06532344) | Ono Pharmaceutical Co., Ltd. | 2021-07-30 |
| An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer (NCT06542731) | Ono Pharmaceutical Co., Ltd. | 2021-06-01 |
| An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (NCT06538207) | Ono Pharmaceutical Co., Ltd. | 2021-01-13 |
| Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer (NCT06547385) | Ono Pharmaceutical Co., Ltd. | 2021-01-13 |
| A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19) (NCT04657497) | Ono Pharmaceutical Co., Ltd. | 2020-11-09 |
| ONO-4538 Phase II Rollover Study (ONO-4538-98) (NCT04566380) | Ono Pharmaceutical Co., Ltd. | 2020-09-10 |
| A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants (NCT04578028) | Ono Pharmaceutical Co., Ltd. | 2020-08-19 |
| ONO-7913 Phase I Study (ONO-7913) (NCT04403308) | Ono Pharmaceutical Co., Ltd. | 2020-07-28 |
| Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects (NCT04504760) | Ono Pharmaceutical Co., Ltd. | 2020-07-10 |
| Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects (NCT04451083) | Ono Pharmaceutical Co., Ltd. | 2020-07-01 |
| Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects (NCT04079062) | Ono Pharmaceutical Co., Ltd. | 2019-09-12 |
| A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers (NCT03919890) | Ono Pharmaceutical Co., Ltd. | 2019-01-17 |
| Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors (NCT03730337) | Ono Pharmaceutical Co., Ltd. | 2018-10-17 |
| A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers (NCT03571594) | Ono Pharmaceutical Co., Ltd. | 2018-06-07 |